XBIT logo

XBIOTECH INC

XBITNASDAQ
🏆 #4224 by market capUS Equity
$1.85▲ $0.02 (+1.09%)
Latest quote
🔔
Track XBIT
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 1.1%
7d▼ 6.8%
14d▼ 15.1%
30d▼ 15.1%
ytd▼ 21.3%
1y▼ 22.3%
🏦Market Cap
$56M
Small Cap
📈Revenue Growth (YoY)
0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$1.85 – $1.85
52-Week Range
$1.81 – $3.44
Volume (shares)
560
Avg Volume (shares)
—
Shares Outstanding
30.5M
Next Earnings
—

Fundamentals Snapshot

Annual Revenue
—
Last Q Revenue
—
P/E Ratio
-1.3
P/S Ratio
0.0x
EPS (TTM)
$-1.48
Dividend Yield
0.00%
Dilution (1yr)
+0.1%
XBIT logo

XBIOTECH INC

XBIT
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
83.8%▲ +22.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$56M▲ +31.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$40M▲ +24.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
30.5M▲ +0.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$126M▼ −$37M YoY
StockOtter · stockotter.space

About XBIOTECH INC

XBiotech Inc. is a biopharmaceutical firm specializing in the discovery, development, and commercialization of True Human monoclonal antibodies. Their primary focus involves building a robust pipeline of product candidates aimed at combating both inflammatory and infectious diseases. Furthermore, the company is advancing interleukin-1 alpha-based therapies, which are designed to address a broad spectrum of medical conditions such as cancer, stroke, heart attack, and arthritis. Interleukin-1 alpha itself plays a crucial role in biological processes like tissue breakdown, angiogenesis, blood clot formation, malaise, muscle wasting, and inflammation. Additionally, XBiotech is developing a True Human COVID-19 therapy specifically targeting mutant strains of the virus. Established in 2005, XBiotech Inc. maintains its headquarters in Austin, Texas.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100

Analyst Ratings

ⓘ
Consensus
Buy
7 analysts
Strong Buy2
Buy4
Hold1
Sell0
Strong Sell0
Ratings as of Dec 2021

Latest News & Updates

News unavailable.